-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Monoclonal antibody drugs have great potential in the treatment of autoimmune diseases.
Currently, antibody drugs approved for the treatment of autoimmune diseases in the world can be roughly divided into TNF, interleukins, and integrins.
, B cell depletion and inhibitory targets, and T cell depletion targets
.
Among them, TNFα antibody drugs mainly include infliximab, adalimumab, etanercept, etc.
targeting TNF-α, which are used for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, etc.
immune disease
.
According to data from Huajin Securities, there are currently about 40 TNF-α drugs approved for listing in the world, of which adalimumab is the most approved, followed by infliximab
.
In the domestic market, in recent years, with the continuous entry of infliximab and adalimumab biosimilar companies, the TNF-α antibody drug market has become more competitive, and product price reductions have become a trend
.
For example, recently, the Shaanxi Provincial Public Resources Trading Center issued a notice on the dynamic adjustment of drug products listed on the Internet to lower the price
.
The notice shows that the online price of Infliximab for injection (specification: 100mg/bottle) of Maibotec Pharmaceuticals was adjusted to 1,268 yuan from the original 1,288 yuan
.
Infliximab is a human-mouse chimeric monoclonal antibody developed by Johnson & Johnson / Merck & Co.
that specifically blocks tumor necrosis factor (TNF-α)
.
It was approved by the US FDA in 1998 and entered the Chinese market in 2006 under the trade name of Leike
.
At present, the product has been approved for multiple indications in China, including ulcerative colitis, Crohn's disease, active rheumatoid arthritis, active ankylosing spondylitis, plaque psoriasis,
etc.
Leike is facing the impact of biosimilars and interleukin inhibitors.
On July 12, 2021, Mabotek Pharmaceutical's infliximab for injection was approved for marketing, becoming the first infliximab biosimilar in China ; Two months later, Hisun Bio's infliximab for injection was also approved for marketing; in addition, on February 28, 2022, Jiahe Bio's infliximab biosimilar was approved for marketing, and currently domestic infliximab There are already three
.
Judging from the sales data of Leike, in 2020, Leike's global sales revenue was 4.
077 billion US dollars, but by 2021, it has fallen to 3.
489 billion US dollars
.
The competition among generic drug companies is also very fierce.
It can be seen that although the infliximab injection of Mabtech Pharmaceuticals is the first infliximab biosimilar in China, the price will inevitably drop
.
There are also similar products that have also undergone price adjustments.
According to data, Hisun Pharmaceutical's infliximab for injection 100mg won the bid price of 1,288 yuan in Shaanxi Province, and Xi'an Janssen's infliximab for injection 100mg was previously sold in Shaanxi.
The provincial winning bid price is 5,160 yuan
.
In order to increase market share, Maibotec is still actively seeking cooperation recently
.
On March 31, 2022, Sinovac and Mabtech announced the signing of the "Infliximab Exclusive Promotion Service Agreement in the Mainland China Market", granting the company the exclusive rights to promote infliximab in the mainland, and the company will pay Mabel Taike's exclusive promotion license fee is 150 million yuan
.
As early as June 28, 2021, Maibotec Pharmaceuticals reached a cooperation with Kexing Pharmaceuticals, granting the latter the commercialization rights of infliximab in the overseas cooperation area
.
It is reported that since the launch of the drug in July 2021, Sinovac has started registration in 32 overseas countries
.
After winning the domestic promotion rights this time, it may have a positive impact on the performance of Kexing Pharmaceuticals
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Currently, antibody drugs approved for the treatment of autoimmune diseases in the world can be roughly divided into TNF, interleukins, and integrins.
, B cell depletion and inhibitory targets, and T cell depletion targets
.
Among them, TNFα antibody drugs mainly include infliximab, adalimumab, etanercept, etc.
targeting TNF-α, which are used for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, etc.
immune disease
.
According to data from Huajin Securities, there are currently about 40 TNF-α drugs approved for listing in the world, of which adalimumab is the most approved, followed by infliximab
.
In the domestic market, in recent years, with the continuous entry of infliximab and adalimumab biosimilar companies, the TNF-α antibody drug market has become more competitive, and product price reductions have become a trend
.
For example, recently, the Shaanxi Provincial Public Resources Trading Center issued a notice on the dynamic adjustment of drug products listed on the Internet to lower the price
.
The notice shows that the online price of Infliximab for injection (specification: 100mg/bottle) of Maibotec Pharmaceuticals was adjusted to 1,268 yuan from the original 1,288 yuan
.
Infliximab is a human-mouse chimeric monoclonal antibody developed by Johnson & Johnson / Merck & Co.
that specifically blocks tumor necrosis factor (TNF-α)
.
It was approved by the US FDA in 1998 and entered the Chinese market in 2006 under the trade name of Leike
.
At present, the product has been approved for multiple indications in China, including ulcerative colitis, Crohn's disease, active rheumatoid arthritis, active ankylosing spondylitis, plaque psoriasis,
etc.
Leike is facing the impact of biosimilars and interleukin inhibitors.
On July 12, 2021, Mabotek Pharmaceutical's infliximab for injection was approved for marketing, becoming the first infliximab biosimilar in China ; Two months later, Hisun Bio's infliximab for injection was also approved for marketing; in addition, on February 28, 2022, Jiahe Bio's infliximab biosimilar was approved for marketing, and currently domestic infliximab There are already three
.
Judging from the sales data of Leike, in 2020, Leike's global sales revenue was 4.
077 billion US dollars, but by 2021, it has fallen to 3.
489 billion US dollars
.
The competition among generic drug companies is also very fierce.
It can be seen that although the infliximab injection of Mabtech Pharmaceuticals is the first infliximab biosimilar in China, the price will inevitably drop
.
There are also similar products that have also undergone price adjustments.
According to data, Hisun Pharmaceutical's infliximab for injection 100mg won the bid price of 1,288 yuan in Shaanxi Province, and Xi'an Janssen's infliximab for injection 100mg was previously sold in Shaanxi.
The provincial winning bid price is 5,160 yuan
.
In order to increase market share, Maibotec is still actively seeking cooperation recently
.
On March 31, 2022, Sinovac and Mabtech announced the signing of the "Infliximab Exclusive Promotion Service Agreement in the Mainland China Market", granting the company the exclusive rights to promote infliximab in the mainland, and the company will pay Mabel Taike's exclusive promotion license fee is 150 million yuan
.
As early as June 28, 2021, Maibotec Pharmaceuticals reached a cooperation with Kexing Pharmaceuticals, granting the latter the commercialization rights of infliximab in the overseas cooperation area
.
It is reported that since the launch of the drug in July 2021, Sinovac has started registration in 32 overseas countries
.
After winning the domestic promotion rights this time, it may have a positive impact on the performance of Kexing Pharmaceuticals
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
